Literature DB >> 27517355

Atopic Dermatitis: Update for Pediatricians.

Katherine Grey, Sheilagh Maguiness.   

Abstract

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder present in up to 20% of children. Recent advances implicate skin barrier dysfunction as central to disease pathogenesis. Genetic defects in the filaggrin gene, the product of which is important for maintaining the epidermal barrier, are a strong predisposing factor in the development of AD. In addition to reducing identifiable triggers, treatment should focus on the four clinical characteristics of eczema: emollients for dry skin, topical anti-inflammatory agents to reduce inflammation and itch, and strategies to reduce infection/colonization, which can include diluted bleach baths. New studies demonstrate that early emollient application from birth may prevent development of AD. [Pediatr Ann. 2016;45(8):e280-e286.]. Copyright 2016, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27517355     DOI: 10.3928/19382359-20160720-05

Source DB:  PubMed          Journal:  Pediatr Ann        ISSN: 0090-4481            Impact factor:   1.132


  3 in total

1.  Hygiene practices: Are they protective factors for eczema symptoms?

Authors:  David Ferrandiz-Mont; Nur Wahyuniati; Hsin-Jen Chen; Mulyadi Mulyadi; Tjut Mariam Zanaria; Dar-Der Ji
Journal:  Immun Inflamm Dis       Date:  2018-03-07

2.  Inhibitory Activity of Allergic Contact Dermatitis and Atopic Dermatitis-Like Skin in BALB/c Mouse through Oral Administration of Fermented Barks of Alnus sibirica.

Authors:  Jun Yin; Seong Hye Yoon; Hye Shin Ahn; Min Won Lee
Journal:  Molecules       Date:  2018-02-18       Impact factor: 4.411

Review 3.  Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.

Authors:  Huiying Wan; Haiping Jia; Tian Xia; Dingding Zhang
Journal:  Dermatol Ther       Date:  2022-07-27       Impact factor: 3.858

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.